Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.
The Lancet2h
A new pathway for primary aldosteronism treatment
An oft-repeated message is that primary aldosteronism is not rare; it is quite common. An equally urgent message is that ...
Fred Hutch5h
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch
A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in ...
News Medical on MSN13h
ESCAPE-MeVO trial advances understanding of stroke treatment for medium-sized vessel blockages
University of Calgary's Hotchkiss Brain Institute researchers with the Calgary Stroke Program at Foothills Medical Centre revolutionized treatment for stroke with the ESCAPE Trial, proving that a clot ...